text_1: • 大多数 免疫 相关 不良 事件 为 1 级 或 2 级 , durvalumab 联合 化疗 组和 单独 化疗 组 的 发生率 分别 为 20% 和 3% .
  
text_2: the majority of immune @-@ related adverse events were grade 1 or 2 and were experienced by 20 % in the durvalumab arm and 3 % in the chemotherapy @-@ alone arm .
  